CTChristoph Trenk

Christoph Trenk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christoph Trenk has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Andreea C. Luca

    Division of Endocrinology & Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria

    1 shared publication
  • Anna C. Obenauf

    Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria

    1 shared publication
  • Balazs Dome

    Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary; National Koranyi Institute of Pulmonology, Budapest, Hungary; Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Translational Medicine, Lund University, Lund, Sweden

    1 shared publication
  • Balázs Győrffy

    MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, and 2nd Department of Pediatrics, Semmelweis University, HU-1117 Budapest, Hungary

    1 shared publication
  • Christiane Ferran

    Beth Israel Deaconess Medical Center, Harvard Medical School

    1 shared publication
  • Dagmar Stoiber

    Division of Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria

    1 shared publication

Latest Publications

  • Down-regulation of A20 promotes immune escape of lung adenocarcinomas

    by Kristina Breitenecker, Monika Homolya, Andreea C. Luca, Veronika Lang, Christoph Trenk, Georg Petroczi, Julian Mohrherr, Jaqueline Horvath, Stefan Moritsch, Lisa Haas, et al.

    Inflammation is a well-known driver of lung tumorigenesis. One strategy by which tumor cells escape tight homeostatic control is by decreasing the expression of the potent anti-inflammatory protein tumor necrosis factor alpha–induced protein 3 (TNFAIP3), also known as A20. We observed that tumor cell intrinsic loss of A20 markedly enhanced lung tumorigenesis and was associated with reduced CD8+ T cell–mediated immune surveillance in patients with lung cancer and in mouse models. In mice, we observed that this effect was completely dependent on increased cellular sensitivity to interferon-γ (IFN-γ) signaling by aberrant activation of TANK-binding kinase 1 (TBK1) and increased downstream expression and activation of signal transducer and activator of transcription 1 (STAT1). Interrupting this autocrine feed forward loop by knocking out IFN-α/β receptor completely restored infiltration of cytotoxic T cells and rescued loss of A20 depending tumorigenesis. Downstream of STAT1, programmed death ligand 1 (PD-L1) was highly expressed in A20 knockout lung tumors. Accordingly, immune checkpoint blockade (ICB) treatment was highly efficient in mice harboring A20-deficient lung tumors. Furthermore, an A20 loss-of-function gene expression signature positively correlated with survival of melanoma patients treated with anti–programmed cell death protein 1. Together, we have identified A20 as a master immune checkpoint regulating the TBK1–STAT1–PD-L1 axis that may be exploited to improve ICB therapy in patients with lung adenocarcinoma.